| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
VPM peptide does not have a defined pharmacological target. It is a peptide cross-linker used in biomaterials science for the preparation of hydrogels. Its mechanism of action is chemical and physical: the peptide's dithiol groups enable cross-linking of PEG-DA macromonomers to form hydrogels. The peptide is cleavable by proteases, making the resulting hydrogels biodegradable and responsive to enzymatic degradation.
|
|---|---|
| ln Vitro |
Matrix metalloproteinase (MMP)-1 and MMP-2 proteases quickly break the VPM peptide[2]. Proteases can break down VPM-crosslinked microgels in a concentration-dependent way[2].
In vitro, VPM peptide is used as a dithiol protease-cleavable peptide cross-linker for the preparation of PEG hydrogels. The peptide is incorporated into PEG-DA macromonomer backbones to form hydrogels that can be used as biomaterials for cell culture, drug delivery, and tissue engineering applications. The protease-cleavable nature of the peptide allows for the preparation of responsive materials that degrade in the presence of specific enzymes. |
| ln Vivo |
In vivo data for VPM peptide as a therapeutic agent are not available, as the compound is a biomaterial cross-linker used for in vitro and ex vivo applications. The peptide may be used in the preparation of hydrogels that are subsequently evaluated in vivo as drug delivery systems or tissue engineering scaffolds. However, the peptide itself has no established in vivo pharmacokinetic or pharmacodynamic profile as a drug.
|
| Enzyme Assay |
For in vitro hydrogel formation, VPM peptide is used as a cross-linker for PEG-DA macromonomers. Standard protocols involve dissolving the peptide in DMSO or appropriate buffer and mixing with PEG-DA macromonomers. The mixture is then cross-linked using a photoinitiator and UV light to form hydrogels. The mechanical properties of the hydrogels are assessed using rheometry. The degradation of the hydrogels in the presence of proteases is monitored by measuring weight loss or changes in mechanical properties.
|
| Cell Assay |
For in vitro cell-based experiments, VPM peptide-based PEG hydrogels are used as scaffolds for cell culture. Cells are encapsulated in the hydrogels or seeded on the surface. Cell viability, proliferation, and differentiation are assessed using standard assays (e.g., MTT, Live/Dead staining). The hydrogels' protease-cleavable properties allow for the study of cell-mediated degradation and the effects of matrix remodeling on cell behavior.
|
| Animal Protocol |
In vivo animal studies using VPM peptide are conducted on the hydrogels prepared from it, not on the peptide itself. PEG hydrogels containing VPM peptide as a cross-linker may be implanted subcutaneously or in other tissues in rodents. The biocompatibility, degradation, and tissue integration of the hydrogels are assessed histologically and by measuring inflammatory responses. The hydrogels' ability to deliver drugs or support tissue regeneration is evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for VPM peptide are not available, as the compound is not a drug and is not administered to living organisms. The peptide has a molecular weight of 1696.95 g/mol. When incorporated into hydrogels, the peptide is retained within the hydrogel matrix until it is degraded by proteases. The degradation products are peptides and amino acids that are metabolized through normal pathways. The compound is primarily used as a biomaterial cross-linker rather than as a drug candidate.
|
| Toxicity/Toxicokinetics |
VPM peptide is a research chemical and should be handled with appropriate laboratory safety precautions. As a peptide, it is generally considered to have low toxicity. The compound should be stored at -20°C, protected from light, and kept dry and sealed. Specific LD₅₀ values and acute toxicity classifications are not available in the public literature. Standard safety practices include the use of personal protective equipment.
|
| References | |
| Additional Infomation |
VPM peptide (CAS 1428885-83-9) is a research-grade peptide cross-linker, not an FDA-approved pharmaceutical drug. Its primary application is as a dithiol protease-cleavable cross-linker for the preparation of PEG hydrogels for biomaterials research. The peptide's protease-cleavable nature makes it useful for the development of biodegradable and responsive hydrogels for cell culture, drug delivery, and tissue engineering applications. No clinical trials or approved therapeutic indications exist for this peptide.
|
| Molecular Formula |
C63H109N25O22S4
|
|---|---|
| Molecular Weight |
1696.9538667202
|
| Exact Mass |
1695.706
|
| CAS # |
1428885-83-9
|
| Related CAS # |
VPM peptide TFA
|
| PubChem CID |
168013115
|
| Appearance |
White to off-white solid powder
|
| LogP |
-12.4
|
| Hydrogen Bond Donor Count |
27
|
| Hydrogen Bond Acceptor Count |
30
|
| Rotatable Bond Count |
56
|
| Heavy Atom Count |
114
|
| Complexity |
3410
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)CN
|
| InChi Key |
CTKJLRUZIZTZBG-YXEJSSDOSA-N
|
| InChi Code |
InChI=1S/C63H109N25O22S4/c1-30(2)48(87-56(106)37(22-46(95)96)84-51(101)32(10-6-16-72-62(67)68)81-58(108)40(29-112)78-42(90)23-64)60(110)88-18-8-12-41(88)59(109)83-35(14-20-114-4)54(104)85-38(27-89)57(107)82-34(13-19-113-3)53(103)79-31(9-5-15-71-61(65)66)49(99)75-24-43(91)74-25-44(92)77-36(21-45(93)94)55(105)80-33(11-7-17-73-63(69)70)52(102)86-39(28-111)50(100)76-26-47(97)98/h30-41,48,89,111-112H,5-29,64H2,1-4H3,(H,74,91)(H,75,99)(H,76,100)(H,77,92)(H,78,90)(H,79,103)(H,80,105)(H,81,108)(H,82,107)(H,83,109)(H,84,101)(H,85,104)(H,86,102)(H,87,106)(H,93,94)(H,95,96)(H,97,98)(H4,65,66,71)(H4,67,68,72)(H4,69,70,73)/t31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,48-/m0/s1
|
| Chemical Name |
(3S)-3-[[2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[(2-aminoacetyl)amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]acetyl]amino]-4-[[(2S)-1-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (29.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (1.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5893 mL | 2.9465 mL | 5.8929 mL | |
| 5 mM | 0.1179 mL | 0.5893 mL | 1.1786 mL | |
| 10 mM | 0.0589 mL | 0.2946 mL | 0.5893 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
